Content area

|
|

Monoklonal gammopati med ubestemt signifikans

Forfatter(e)
Niels Emil Ulrich Hermansen1, Trine Silkjær2, Charlotte Toftmann Hansen3, Thomas Granum Aagaard4 & Henrik Gregersen5

1) Hæmatologisk Afdeling, Sjællands Universitetshospital, Roskilde, 2) Blodsygdomme, Aarhus Universitetshospital, 3) Hæmatologisk Afdeling, Odense Universitetshospital, 4) Afdeling for Blodsygdomme, Herlev og Gentofte Hospital, 5) Hæmatologisk Afdeling, Aalborg Universitetshospital

Ugeskr Læger 2020;182:V08190428

Reference: 
Ugeskr Læger 2020;182:V08190428
Blad nummer: 

Niels Emil Ulrich Hermansen, Trine Silkjær, Charlotte Toftmann Hansen, Thomas Granum Aagaard & Henrik Gregersen:

Monoclonal gammopathy of undetermined significance

Ugeskr Læger 2020;182:V08190428

This review summarises the work-up of patients with monoclonal gammopathy of undetermined significance (MGUS). In persons above 70 years of age, around 5% have MGUS, a premalignant state with a monoclonal plasma immunoglobulin or light chain (M protein) in blood and/or urine. Continuous follow-up is recommended due to a risk of malignant progression of around 1% per year. Immunoglobulin M MGUS primarily progresses to Waldenström’s macroglobulinaemia, whereas non-immunoglobulin M MGUS typically progresses to multiple myeloma or amyloid light-chain amyloidosis. Treatment is unnecessary unless in rare cases of severe non-malignant complications. Screening is not advised.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Henning Bagger | 21/10
1 Kommentar
af Jens Meyer Svendsen | 21/10
2 kommentarer
af Sven Refslund Poulsen | 16/10
1 Kommentar
af Jens Ole Mathiesen | 16/10
1 Kommentar
af Gunnar Lauge Nielsen | 13/10
1 Kommentar
af Morten Krogh Jensen | 13/10
11 kommentarer
af Frank Østergaard Hansen | 12/10
1 Kommentar